Muparfostat sodium

N/A

Report date: 2022/05/18 13:46:20
NME

Base Information

Drug NameMuparfostat sodium
Drug Alias Name磺酸化单磷酸甘露寡聚糖sulfated oligosaccharidessulfated mannopentaose phosphatephosphomannopentaose sulfatePI-88
ClassificationSmall molecules > Carbohydrate
Mechanisms of ActionFibroblast growth factor 1 inhibitorsFibroblast growth factor 2 inhibitorsVascular endothelial growth factor A inhibitors
TargetsFibroblast growth factor 2Fibroblast growth factor 1Vascular endothelial growth factor A
Therapy Area/IndicationsSkin MelanomaSolid tumoursProstatic Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSingapore +[12] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAustralian National University
China Registration ClassN/A

Develop Information

Active CompaniesMedigen Biotechnology Corp
Inactive CompaniesProgen PharmaceuticalsCellxpert Biotechnology Corp
Active IndicationsCarcinoma, Hepatocellular
Inactive IndicationsSkin MelanomaSolid tumoursProstatic Neoplasms +[8] 

Other Information

ATC CodeN/A
Related LinksN/A